MiniMed analysis shows high rates of time in range
By HME News Staff
Updated 9:59 AM CDT, Thu June 3, 2021
DUBLIN, Ireland – Diabetes patients using Medtronics’ MiniMed 780G system saw an average overall time in range of 76.2% and an overnight time in range of 83%, according to an analysis of 4,120 individuals with Type 1 diabetes. "It is extremely encouraging to see Medtronic advancing both clinical outcomes, as well as the user experience through their latest MiniMed 780G system,” said Prof. Chantal Mathieu, endocrinologist at University Hospitals Leuven-KULeuven, Belgium. “It is clear that learnings from the launch of the world's first hybrid closed loop informed the design of this next-generation system. I am confident in this system's ability to do what a person with diabetes may not be able to do on their own by helping them minimize highs and lows, and ultimately live their lives less burdened by their diabetes." Users remained in Advanced Hybrid Closed Loop (AHCL) mode, also referred to as the SmartGuard algorithm, for an average of 94% of the time, and showed an overall reduction in interactions required with the system demonstrated a more seamless experience than previous insulin pump systems, according to the analysis.
Comments